These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 10657972)

  • 1. A defect in a single allele of the Mlh1 gene causes dissociation of the killing and tumorigenic actions of an alkylating carcinogen in methyltransferase-deficient mice.
    Kawate H; Itoh R; Sakumi K; Nakabeppu Y; Tsuzuki T; Ide F; Ishikawa T; Noda T; Nawata H; Sekiguchi M
    Carcinogenesis; 2000 Feb; 21(2):301-5. PubMed ID: 10657972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Separation of killing and tumorigenic effects of an alkylating agent in mice defective in two of the DNA repair genes.
    Kawate H; Sakumi K; Tsuzuki T; Nakatsuru Y; Ishikawa T; Takahashi S; Takano H; Noda T; Sekiguchi M
    Proc Natl Acad Sci U S A; 1998 Apr; 95(9):5116-20. PubMed ID: 9560238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Roles of MGMT and MLH1 proteins in alkylation-induced apoptosis and mutagenesis.
    Takagi Y; Takahashi M; Sanada M; Ito R; Yamaizumi M; Sekiguchi M
    DNA Repair (Amst); 2003 Oct; 2(10):1135-46. PubMed ID: 13679151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mice over-expressing human O6 alkylguanine-DNA alkyltransferase selectively reduce O6 methylguanine mediated carcinogenic mutations to threshold levels after N-methyl-N-nitrosourea.
    Allay E; Veigl M; Gerson SL
    Oncogene; 1999 Jun; 18(25):3783-7. PubMed ID: 10391687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transgenic expression of human MGMT blocks the hypersensitivity of PMS2-deficient mice to low dose MNU thymic lymphomagenesis.
    Qin X; Zhou H; Liu L; Gerson SL
    Carcinogenesis; 1999 Sep; 20(9):1667-73. PubMed ID: 10469609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of human O6-alkylguanine DNA alkyltransferase (AGT) prevents MNU induced lymphomas in heterozygous p53 deficient mice.
    Reese JS; Allay E; Gerson SL
    Oncogene; 2001 Aug; 20(38):5258-63. PubMed ID: 11536039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potentiation of lymphomagenesis by methylnitrosourea in mice transgenic for LMO1 is blocked by O6-alkylguanine DNA-alkyltransferase.
    Allay E; Reese JS; McGuire EA; Koç ON; Sedransk N; Gerson SL
    Oncogene; 1997 Oct; 15(17):2127-32. PubMed ID: 9366529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Killing and mutagenic actions of dacarbazine, a chemotherapeutic alkylating agent, on human and mouse cells: effects of Mgmt and Mlh1 mutations.
    Sanada M; Takagi Y; Ito R; Sekiguchi M
    DNA Repair (Amst); 2004 Apr; 3(4):413-20. PubMed ID: 15010317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mice defective in the DNA mismatch gene PMS2 are hypersensitive to MNU induced thymic lymphoma and are partially protected by transgenic expression of human MGMT.
    Qin X; Liu L; Gerson SL
    Oncogene; 1999 Jul; 18(30):4394-400. PubMed ID: 10439048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased susceptibility to chemotherapeutic alkylating agents of mice deficient in DNA repair methyltransferase.
    Shiraishi A; Sakumi K; Sekiguchi M
    Carcinogenesis; 2000 Oct; 21(10):1879-83. PubMed ID: 11023546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deficient MGMT and proficient hMLH1 expression renders gallbladder carcinoma cells sensitive to alkylating agents through G2-M cell cycle arrest.
    Sato K; Kitajima Y; Kohya N; Miyoshi A; Koga Y; Miyazaki K
    Int J Oncol; 2005 Jun; 26(6):1653-61. PubMed ID: 15870882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylnitrosourea-induced tumorigenesis in MGMT gene knockout mice.
    Sakumi K; Shiraishi A; Shimizu S; Tsuzuki T; Ishikawa T; Sekiguchi M
    Cancer Res; 1997 Jun; 57(12):2415-8. PubMed ID: 9192819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-associated Apc mutations in Mlh1-/- Apc1638N mice reveal a mutational signature of Mlh1 deficiency.
    Kuraguchi M; Edelmann W; Yang K; Lipkin M; Kucherlapati R; Brown AM
    Oncogene; 2000 Nov; 19(50):5755-63. PubMed ID: 11126362
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA repair methyltransferase (Mgmt) knockout mice are sensitive to the lethal effects of chemotherapeutic alkylating agents.
    Glassner BJ; Weeda G; Allan JM; Broekhof JL; Carls NH; Donker I; Engelward BP; Hampson RJ; Hersmus R; Hickman MJ; Roth RB; Warren HB; Wu MM; Hoeijmakers JH; Samson LD
    Mutagenesis; 1999 May; 14(3):339-47. PubMed ID: 10375003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heterozygous DNA mismatch repair gene PMS2-knockout mice are susceptible to intestinal tumor induction with N-methyl-N-nitrosourea.
    Qin X; Shibata D; Gerson SL
    Carcinogenesis; 2000 Apr; 21(4):833-8. PubMed ID: 10753224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alkyltransferase transgenic mice: probes of chemical carcinogenesis.
    Gerson SL; Zaidi NH; Dumenco LL; Allay E; Fan CY; Liu L; O'Connor PJ
    Mutat Res; 1994 Jun; 307(2):541-55. PubMed ID: 7514728
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alkylation carcinogenesis in mice with altered levels of DNA repair methyltransferase.
    Sekiguchi M; Sanada M
    Prog Exp Tumor Res; 1999; 35():25-36. PubMed ID: 10377749
    [No Abstract]   [Full Text] [Related]  

  • 18. Role of DNA repair in carcinogen-induced ras mutation.
    Engelbergs J; Thomale J; Rajewsky MF
    Mutat Res; 2000 May; 450(1-2):139-53. PubMed ID: 10838139
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MGMT expression in murine bone marrow is a major determinant of animal survival after alkylating agent exposure.
    Reese JS; Qin X; Ballas CB; Sekiguchi M; Gerson SL
    J Hematother Stem Cell Res; 2001 Feb; 10(1):115-23. PubMed ID: 11276365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methylation tolerance due to an O6-methylguanine DNA methyltransferase (MGMT) field defect in the colonic mucosa: an initiating step in the development of mismatch repair-deficient colorectal cancers.
    Svrcek M; Buhard O; Colas C; Coulet F; Dumont S; Massaoudi I; Lamri A; Hamelin R; Cosnes J; Oliveira C; Seruca R; Gaub MP; Legrain M; Collura A; Lascols O; Tiret E; Fléjou JF; Duval A
    Gut; 2010 Nov; 59(11):1516-26. PubMed ID: 20947886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.